{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:17:16Z","timestamp":1789633036894,"version":"build-2803163510"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Infect Dis."],"published-print":{"date-parts":[[2015,11,15]]},"DOI":"10.1093\/cid\/civ571","type":"journal-article","created":{"date-parts":[[2015,7,16]],"date-time":"2015-07-16T00:32:23Z","timestamp":1437006743000},"page":"1558-1565","source":"Crossref","is-referenced-by-count":323,"title":["Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent"],"prefix":"10.1093","volume":"61","author":[{"given":"Marisa H.","family":"Miceli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A.","family":"Kauffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,7,15]]},"reference":[{"key":"2015102207022073000_61.10.1558.1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2012.683859"},{"key":"2015102207022073000_61.10.1558.2","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-010-9324-3"},{"key":"2015102207022073000_61.10.1558.3","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00863-13"},{"key":"2015102207022073000_61.10.1558.4","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-014-9772-2"},{"key":"2015102207022073000_61.10.1558.5","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04055-14"},{"key":"2015102207022073000_61.10.1558.6","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp138"},{"key":"2015102207022073000_61.10.1558.7","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01216-08"},{"key":"2015102207022073000_61.10.1558.8","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00685-10"},{"key":"2015102207022073000_61.10.1558.9","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki399"},{"key":"2015102207022073000_61.10.1558.10","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01530-08"},{"key":"2015102207022073000_61.10.1558.11","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01512-07"},{"key":"2015102207022073000_61.10.1558.12","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00636-13"},{"key":"2015102207022073000_61.10.1558.13","doi-asserted-by":"publisher","DOI":"10.1080\/13693780802562969"},{"key":"2015102207022073000_61.10.1558.14","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2009.21.3.272"},{"key":"2015102207022073000_61.10.1558.15","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr443"},{"key":"2015102207022073000_61.10.1558.16","doi-asserted-by":"publisher","DOI":"10.3201\/eid1710.110226"},{"key":"2015102207022073000_61.10.1558.17","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp109"},{"key":"2015102207022073000_61.10.1558.18","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01629-13"},{"key":"2015102207022073000_61.10.1558.19","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12315"},{"key":"2015102207022073000_61.10.1558.20","unstructured":"Astellas Pharma US. Prescribing information for Cresemba 2015. Available at: www.astellas.us\/docs\/cresemba.pdf . Accessed 12 April 2015."},{"key":"2015102207022073000_61.10.1558.21","unstructured":"US Food and Drug Administration. Isavuconazonium\u2014invasive aspergillosis and invasive mucormycosis. Advisory Committee Briefing Document 2015. Available at: www.FDA.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/anti-infectivedrugsadvisorycommittee\/ucm430748.pdf . Accessed 12 April 2015."},{"key":"2015102207022073000_61.10.1558.22","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.1.279-285.2006"},{"key":"2015102207022073000_61.10.1558.23","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.1.286-293.2006"},{"key":"2015102207022073000_61.10.1558.24","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04569-14"},{"key":"2015102207022073000_61.10.1558.25","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01601-08"},{"key":"2015102207022073000_61.10.1558.26","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00319-09"},{"key":"2015102207022073000_61.10.1558.27","unstructured":"Yamakazi T , Pearlman H , Kowalski D , Lademacher C , Desai A , Townsend R . Effect of multiple doses of isavuconazole on the pharmacokinetics of CYP3A4 substrate atorvastatin in healthy subjects [abstract A-449]. In: Program and abstracts of the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, CO, 2013."},{"key":"2015102207022073000_61.10.1558.28","unstructured":"Yamakazi T , Desai A , Pearlman H , Kowalski D , Lademacher C , Townsend R . No effect on pharmacokinetic and pharmacodynamic parameters of warfarin after coadministration with isavuconazole [abstract A-449]. In: Program and abstracts of the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, CO, 2013."},{"key":"2015102207022073000_61.10.1558.29","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04586-14"},{"key":"2015102207022073000_61.10.1558.30","unstructured":"Marty FM , Perfect JR , Cornely OA et al . An open-label phase 3 study of isavuconazole (VITAL): focus on mucormycosis [abstract 824]. In: Program and abstracts of IDWeek, Philadelphia, PA, 2014."},{"key":"2015102207022073000_61.10.1558.31","unstructured":"Thompson GR 3rd , Rendon A , Santos R et al . Outcomes in patients with invasive fungal disease caused by dimorphic fungi treated with isavuconazole: experience from the VITAL trial [abstract M-1775]. In: Program and abstracts of the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2014."},{"key":"2015102207022073000_61.10.1558.32","unstructured":"Kontoyiannis DP , Giladi M , Lee M et al . A phase 3, randomized, double-blind, non-inferiority trial to evaluate efficacy and safety of isavuconazole versus voriconazole in patients with invasive mold disease (SECURE): outcomes in invasive aspergillosis patients [abstract 1211]. In: Program and abstracts of IDWeek, Philadelphia, PA, 2014."},{"key":"2015102207022073000_61.10.1558.33","unstructured":"Raad I , Mullane KM , Selleslag D et al . A phase 3, randomized, double-blind, non-inferiority trial to evaluate efficacy and safety of isavuconazole vs. voriconazole in patients with invasive mold disease: outcomes in patient with pulmonary infections [abstract 825]. In: Program and abstracts of IDWeek, Philadelphia, PA, 2014."},{"key":"2015102207022073000_61.10.1558.34","unstructured":"Patterson T , Selleslag D , Mullane KM et al . A phase 3, randomized, double-blind, non-inferiority trial to evaluate efficacy and safety of isavuconazole versus voriconazole in patients with invasive mold disease (SECURE): outcomes in neutropenic patients [abstract 1210]. In: Program and abstracts of IDWeek, Philadelphia, PA, 2014."},{"key":"2015102207022073000_61.10.1558.35","doi-asserted-by":"publisher","DOI":"10.1086\/588660"},{"key":"2015102207022073000_61.10.1558.36","doi-asserted-by":"publisher","DOI":"10.1086\/590566"},{"key":"2015102207022073000_61.10.1558.37","doi-asserted-by":"publisher","DOI":"10.1086\/432579"},{"key":"2015102207022073000_61.10.1558.38","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir880"},{"key":"2015102207022073000_61.10.1558.39","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.1.126-133.2006"},{"key":"2015102207022073000_61.10.1558.40","doi-asserted-by":"publisher","DOI":"10.1086\/500212"},{"key":"2015102207022073000_61.10.1558.41","unstructured":"Cornely OA , Ostrosky-Zeichner L , Rahav G et al . Outcomes in patients with invasive mold disease caused by Fusarium or Scedosporium spp. treated with isavuconazole: experience from the VITAL and SECURE trials [abstract M-1760]. In: Program and abstracts of the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2014."}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/61\/10\/1558\/856325\/civ571.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,22]],"date-time":"2017-08-22T21:07:59Z","timestamp":1503436079000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article-lookup\/doi\/10.1093\/cid\/civ571"}},"subtitle":[],"editor":[{"given":"Louis D.","family":"Saravolatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,7,15]]},"references-count":41,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2015,10,22]]},"published-print":{"date-parts":[[2015,11,15]]}},"alternative-id":["10.1093\/cid\/civ571"],"URL":"https:\/\/doi.org\/10.1093\/cid\/civ571","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,15]]}}}